NCT00770302View on ClinicalTrials.gov

Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Type 2 Diabetes
Interventions
DRUG

Saxagliptin

Oral tablet, once daily for 1 (single-dose) and 5 (multiple-dose) days

Trial Locations (1)

Unknown

Research Site, Beijing

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY